Tag: Biosimilars

Delivering Scientific and Service Excellence for 10 Years

28th September 2017

Category: General

Tags: , , , , , ,

By:

In 2007, a team of experienced industry professionals founded BioOutsource Ltd. in Glasgow, UK. This year we are celebrating our 10 year anniversary, and taking a look back at our key milestones and achievements. Follow our story about how we began as a small start-up business to becoming one of the global leaders in contract testing. August More

What is the best way to approach biosimilar development?

27th March 2017

Category: Bioanalytical / Biosimilars

Tags: , , ,

By: Dr Terry Gray, Field Marketing Manager,

Part one Monoclonal antibodies have a highly specific targeted action which allows a reduction in side effects compared to small molecule drugs, which has seen them becoming a mainstay of modern medicine. The innate complexity of these molecules allows them to be potent drugs that activate molecular cascades within the immune system. So what does More

Piecing together the biosimilar puzzle: Physicochemical & Functional Analytics

Category: Bioanalytical / Biosimilars

Tags: , , , , , , , ,

By: Dr Terry Gray, Field Marketing Manager,

Part two Read Part One. A fundamental feature of a mAb is its biological structure, as this defines the functional output of the biologic, as illustrated by Figure 2. Figure 2 – The interplay between the structure of a monoclonal antibody, the affinity for interaction and the resulting functional activity. Fundamentally, the sequence of a More

Psoriatic Arthritis treatment attracts attention for Biosimilar development

2nd February 2015

Category: Biosimilars

Tags: ,

By: Dr Daniel Galbraith, CSO,

Like waiting for a bus, there was no effective treatment for psoriatic arthritis then three came along. The literature has been awash with the new treatments; anti-TNF α drugs such as Enbrel and Humira. Janssens anti-IL-12/23 drug Stelara and now the new IL-17 blocker Secukinumab from Novartis. These drugs have clinically demonstrated to be effective More

Anti-TNF-alpha Biosimilars Humira, Remicade and Enbrel

1st March 2012

Category: Biosimilars

Tags: , , , ,

By: Dr Daniel Galbraith, CSO,

Anti Tumor Necrosis Factor (Anti-TNF) drugs, Humira (adalimumab), Remicade (infliximab) and Enbrel (etanercept) are perhaps the most successful of all biologics both with respect to their turnover and the number of patients treated with these drugs. All have been shown in clinical trials to help with improving the clinical outcome of Rheumatoid Arthritis (RA) but More

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy